June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced that its lead clinical candidate, RBT-1, met the primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning in a pre-specified interim Phase 2 data analysis.
